Drug-eluting stents for acute myocardial infarction.

Abstract:

:This is a review of the literature comparing the efficacy and safety of drug-eluting stents (DES) versus bare-metal stents (BMS) in patients with acute myocardial infarction (MI). The present article reviews whether DES are beneficial in the setting of primary percutaneous coronary intervention (PCI), and this has been the subject of many recent publications and debate among clinicians. To the best of our knowledge there are limited registries and randomized trials about DES for acute MI in the English literature. Bare-metal stents have a higher incidence of instent restenosis whereas DES might have a slightly higher late thrombosis risk. With the current data DES might still have an advantage over BMS in the treatment of ST-segment elevation MI (STEMI) patients with the vastly improved target vessel revascularization rates. Despite the lack of well-designed head-to-head long-term prospective clinical trials, DES may not be effective in patients who are on short-term dual antiplatelet therapy owing to an increased risk of late stent thrombosis. In conclusion, DES use in STEMI patients continuing long-term dual antiplatelet therapy is safe and effective.

authors

Yeter E,Kurt M,Silay Y,Anderson HV,Denktas AE

doi

10.1517/14656560802627952

subject

Has Abstract

pub_date

2009-01-01 00:00:00

pages

19-34

issue

1

eissn

1465-6566

issn

1744-7666

journal_volume

10

pub_type

杂志文章,评审
  • Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs.

    abstract:BACKGROUND:Patients with rheumatoid arthritis (RA) have an increased risk of atherosclerotic cardiovascular disease which cannot be explained by traditional cardiovascular risk factors alone. Atherosclerosis is considered an inflammatory condition and inflammation experienced in RA may contribute to accelerated atheros...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.7.1121

    authors: Avouac J,Allanore Y

    更新日期:2008-05-01 00:00:00

  • Treating diabetic ulcers.

    abstract:INTRODUCTION:Diabetic foot ulceration is a serious secondary complication of diabetes mellitus and the most common cause of hospitalization in diabetic patients. The etiology of diabetic foot ulcerations is complex due to their multifactorial nature. Thus, addressing all of the factors involved remains instrumental in ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.530658

    authors: Tecilazich F,Dinh T,Veves A

    更新日期:2011-03-01 00:00:00

  • Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE) confirms that abaloparatide is a valuable addition to the armamentarium against osteoporosis.

    abstract::The recently published Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE) assessed the efficacy and safety of abaloparatide (80 µg daily subcutaneous) (ABL) vs placebo during 18 months, in postmenopausal osteoporosis. Teriparatide (20 µg daily subcutaneous) (TPD) was used as an open label active comparator...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2017.1395021

    authors: Reginster JY,Al Daghri NM,Bruyere O

    更新日期:2017-12-01 00:00:00

  • Pharmacological management of dementia with Lewy bodies with a focus on zonisamide for treating parkinsonism.

    abstract:INTRODUCTION:Dementia with Lewy bodies (DLB) has no approved symptomatic or disease-modifying treatments in the US and Europe, despite being the second most common cause of neurodegenerative dementia. AREAS COVERED:Herein, the authors briefly review the DLB drug development pipeline, providing a summary of the current...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2020.1828350

    authors: Panza F,Lozupone M,Watling M,Imbimbo BP

    更新日期:2020-10-06 00:00:00

  • Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries.

    abstract:INTRODUCTION:In this review, the authors describe medications in phase III of clinical development for schizophrenia and schizoaffective disorder, and provide an opinion on how current treatment can be improved in the near future. AREAS COVERED:Recent (post 2013) phase III clinical trials of schizophrenia-targeted the...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2016.1149164

    authors: Garay RP,Citrome L,Samalin L,Liu CC,Thomsen MS,Correll CU,Hameg A,Llorca PM

    更新日期:2016-01-01 00:00:00

  • Recent developments in antibiotic agents for the treatment of complicated intra-abdominal infections.

    abstract:INTRODUCTION:Treatment of complicated intra-abdominal infections (cIAIs) is becoming increasingly difficult because of the widespread emergence of multidrug-resistant organisms. AREAS COVERED:In this review, we discuss the effectiveness of several new antibiotics for the treatment of cIAIs, including new β-lactamase i...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2016.1122756

    authors: Lin SY,Huang CH,Ko WC,Chen YH,Hsueh PR

    更新日期:2016-01-01 00:00:00

  • Current and future treatments of alopecia areata and trichotillomania in children.

    abstract:INTRODUCTION:Treatment options for hair disorders are generally very limited. These options are even more limited in children due to the lack of trials and clinical research. Moreover, physicians are sometimes scared to treat children with drugs without safety data, especially because most hair disorders are benign. A...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2016.1217990

    authors: Iorizzo M,Oranje AP

    更新日期:2016-09-01 00:00:00

  • The optimal pharmacological formula for percutaneous coronary intervention.

    abstract:INTRODUCTION:Adjunctive pharmacotherapy is of key importance in determining the outcomes of percutaneous coronary intervention (PCI). In parallel, there has been an increasing body of evidence indicating that the aggressive management of coronary risk factors and changes in lifestyle behavior yield additional positive ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.546345

    authors: Capodanno D,Tamburino C,Dangas G

    更新日期:2011-05-01 00:00:00

  • Association between antidepressants and breast/ovarian cancer.

    abstract:INTRODUCTION:Women are more vulnerable to the development of major depressive disorder (MDD) than men. Although several epidemiological studies have investigated the association between antidepressants and the risk of developing cancer, different methodologies were applied and as a result most of the results were incon...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 评论,杂志文章

    doi:10.1517/14656566.2012.647684

    authors: Pae CU

    更新日期:2012-02-01 00:00:00

  • Pharmacological management of depression in patients with multiple sclerosis.

    abstract:INTRODUCTION:The pharmacotherapeutic management of depression in patients with multiple sclerosis (MS) is a matter of debate that cannot be decided from the evidence available in the current literature. Therefore, its management essentially relies on the clinical experience of the prescribing clinician rather than on e...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1516207

    authors: Carta MG,Paribello P,Anastasia A,De Berardis D,Nardi AE,Fornaro M

    更新日期:2018-10-01 00:00:00

  • Emerging therapies for ionizing radiation-associated skin field carcinogenesis.

    abstract:BACKGROUND:Radiodermatitis in its acute and chronic presentations represents a set of specific adverse effects resulting from ionizing radiations. Skin-field cancerization is another condition associated to or independent of clinically recognizable radiodermatitis. This condition leads to the risk of later occurrence o...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560902754060

    authors: Piérard GE,Piérard-Franchimont C,Paquet P,Quatresooz P

    更新日期:2009-04-01 00:00:00

  • Pharmacotherapies for the treatment of glioblastoma - current evidence and perspectives.

    abstract:INTRODUCTION:Glioblastoma, the most common malignant brain tumor, exhibits a poor prognosis with little therapeutic progress in the last decade. Novel treatment strategies beyond the established standard of care with temozolomide-based radiotherapy are urgently needed. AREAS COVERED:We reviewed the literature on gliob...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2016.1176146

    authors: Seystahl K,Gramatzki D,Roth P,Weller M

    更新日期:2016-06-01 00:00:00

  • TNF blockade in the treatment of rheumatoid arthritis: infliximab versus etanercept.

    abstract::There is accumulating evidence that tumour necrosis factor (TNF) plays a major role in the pathogenesis of rheumatoid arthritis (RA). Recent biotechnological advances have allowed for the development of agents that directly target TNF, a pro-inflammatory cytokine. In the last 2 years, the US FDA and the EU's Commissio...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2.1.75

    authors: Mikuls TR,Moreland LW

    更新日期:2001-01-01 00:00:00

  • Pharmacological management of renal fibrotic disease.

    abstract::Chronic kidney diseases frequently advance to end-stage renal failure, and the number of patients affected is steadily increasing worldwide. At the molecular level, progression of renal insufficiency correlates closely with ongoing pathological matrix protein expansion (i.e., renal fibrosis), in a manner independent o...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.7.4.377

    authors: Gaedeke J,Neumayer HH,Peters H

    更新日期:2006-03-01 00:00:00

  • Miconazole, a pharmacological barrier to skin fungal infections.

    abstract:INTRODUCTION:Miconazole (MCZ) is a time-honored antifungal of the imidazole class. MCZ exerts a multipronged effect on fungi. It inhibits the cytochrome P450 complex, including the 14α-demethylase enzyme required for ergosterol biosynthesis, in fungal cell membranes. In addition, intracellular accumulation of toxic met...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.687047

    authors: Piérard GE,Hermanns-Lê T,Delvenne P,Piérard-Franchimont C

    更新日期:2012-06-01 00:00:00

  • Amifostine: chemotherapeutic and radiotherapeutic protective effects.

    abstract::Amifostine (Ethyoltrade mark, Alza Pharmaceuticals) is an inorganic thiophosphate cytoprotective agent known chemically as ethanethiol, 2-[3- aminopropyl)amino]dihydrogen phosphate. It is a prodrug of free thiol (WR-1065) that may act as a scavenger of free radicals generated in tissues exposed to cytotoxic drugs and ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2.3.479

    authors: Santini V

    更新日期:2001-03-01 00:00:00

  • Anti-TNF-alpha therapy in ankylosing spondylitis.

    abstract::Ankylosing spondylitis (AS) is a frequent disease leading to functional impairment and socioeconomic burden. Anti-TNF-alpha therapy has brought new perspectives in this condition. Two agents are currently used in the treatment of AS and spondyloarthropathies - infliximab (a chimeric monoclonal antibody) and etanercept...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.5.7.1497

    authors: Wendling D,Toussirot E

    更新日期:2004-07-01 00:00:00

  • Palliative treatment of unresectable metastatic colorectal cancer.

    abstract:IMPORTANCE OF THE FIELD:Treatment options for metastatic colorectal cancer (mCRC) patients have rapidly increased in the past years, but 50 - 70% of mCRC patients are still unlikely to undergo radical resection of metastases and are candidates for palliative therapy only. AREAS COVERED IN THIS REVIEW:Oxaliplatin and i...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560903427997

    authors: Fornaro L,Masi G,Loupakis F,Vasile E,Falcone A

    更新日期:2010-01-01 00:00:00

  • Emerging antiretroviral drugs.

    abstract:INTRODUCTION:The potency, tolerability and convenience of antiretroviral agents have all significantly improved over the past years, making lifelong HIV therapy easier. However, several specific needs are still unmet, including low daily pill burden, friendly metabolic profile, lack of (or few) drug interactions and hi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.863277

    authors: Fernández-Montero JV,Vispo E,Soriano V

    更新日期:2014-02-01 00:00:00

  • Cytotoxic and molecular chemotherapy for high-grade glioma: an emerging strategy for the future.

    abstract::Maximal surgical debulking and radiotherapy have been the cornerstone of therapy for high-grade gliomas. The impact of chemotherapy on outcome has been marginal and, until recently, its usage has been debatable. The development of new drugs and an improved understanding of chemoresistance have reinvigorated interest i...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.7.6.749

    authors: Cavaliere R,Newton H

    更新日期:2006-04-01 00:00:00

  • Vaginal ring delivery of hormone replacement therapy--a review.

    abstract::Vaginal ring delivery systems are a highly promising approach to hormone replacement therapy (HRT). The vagina is an excellent route for steroid absorption. Menopausal vaginal rings can be designed to allow very low dose local delivery of oestrogen to the vagina for the large percentage of postmenopausal women experie...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.2.201

    authors: Dezarnaulds G,Fraser IS

    更新日期:2003-02-01 00:00:00

  • Ras/Raf signalling and emerging pharmacotherapeutic targets.

    abstract::The Ras-Raf-MEK-ERK pathway is a ubiquitously expressed signalling module that regulates the proliferation, differentiation and survival of cells. This pathway features several oncogenes and is deregulated in approximately 30% of all human cancers. Thus, it has emerged as a prime target for antitumour therapy. Drugs t...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.3.6.709

    authors: Kolch W

    更新日期:2002-06-01 00:00:00

  • Advances in orally administered pharmacotherapy for the treatment of migraine.

    abstract:INTRODUCTION:Migraine is a common and highly disabling neurological disorder whose acute treatment remains problematic and unsatisfactory in a high percentage of cases. Consequently, there remains a need for new symptomatic therapies that can be easily handled by patients (i.e. by oral administration). AREAS COVERED:T...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1549223

    authors: Martelletti P,Giamberardino MA

    更新日期:2019-02-01 00:00:00

  • Ramipril in the treatment of vascular diseases.

    abstract::Ramipril is an angiotensin-converting enzyme inhibitor that has been extensively studied in randomised, controlled clinical trials in patients with cardiovascular diseases. Therapy with ramipril in patients with various cardiovascular disorders has demonstrated significant and clinically important reductions in cardio...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.11.1911

    authors: Rokoss MJ,Teo KK

    更新日期:2005-09-01 00:00:00

  • Ziprasidone for maintenance treatment of bipolar I disorder in adults.

    abstract:INTRODUCTION:Antipsychotic drugs are increasingly used in the maintenance treatment of bipolar disorder. This review addresses the evidence supporting the use of one of these medications for this indication in order to place available data in perspective for the clinician. AREAS COVERED:The approval of ziprasidone for...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656566.2011.563237

    authors: Dubovsky SL,Dubovsky AN

    更新日期:2011-04-01 00:00:00

  • Safinamide in the treatment of Parkinson's disease.

    abstract:IMPORTANCE OF THE FIELD:Current therapy for Parkinson's disease (PD) is primarily directed at reversing the motor symptoms that are the consequence of dopamine deficiency and includes levodopa, dopamine agonists and monoamine oxidase (MAO) B inhibitors. New drugs offering both dopaminergic and non-dopaminergic actions ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2010.511612

    authors: Schapira AH

    更新日期:2010-09-01 00:00:00

  • Topical alprostadil cream for the treatment of erectile dysfunction.

    abstract::Erectile dysfunction (ED) has serious negative consequences on both sexual experience and emotional well being and affects a broad range of age groups. The prevalence of ED is associated with increasing age and has been reported to be as high as 70%. Although the disorder is common and underdiagnosed, its treatment ca...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.5.3.623

    authors: Becher E

    更新日期:2004-03-01 00:00:00

  • Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.

    abstract:INTRODUCTION:Many patients with type 2 diabetes mellitus (T2DM) fail to achieve the desired A1c goal because the antidiabetic medications used do not correct the underlying pathophysiologic abnormalities and monotherapy is not sufficiently potent to reduce the A1c to the 6.5 - 7.0% range. Insulin resistance and islet (...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1114098

    authors: Triplitt C,Solis-Herrera C,Cersosimo E,Abdul-Ghani M,Defronzo RA

    更新日期:2015-01-01 00:00:00

  • Comparison between insulin degludec/liraglutide treatment and insulin glargine/lixisenatide treatment in type 2 diabetes: a systematic review and meta-analysis.

    abstract:AIM:To evaluate the efficacy and adverse effects of IDegLira and IGlarLixi treatment and to perform a comparison between two strategies. METHODS:The registration number is CRD42017053952. Randomized controlled trials of IGlarLixi treatment or IDegLira treatment compared with placebo or active hypoglycemic agents in ty...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,meta分析,评审

    doi:10.1080/14656566.2017.1400011

    authors: Cai X,Gao X,Yang W,Ji L

    更新日期:2017-12-01 00:00:00

  • Dexmethylphenidate for attention deficit hyperactivity disorder.

    abstract:BACKGROUND:Dexmethylphenidate is a single-isomer stimulant medication approved for the treatment of attention deficit hyperactivity disorder (ADHD). Single-isomer drugs have the potential for decreased undesired effects and improved therapeutic efficacy. Stimulant medications have been the mainstay treatments for ADHD ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656560903386284

    authors: Coury D

    更新日期:2009-11-01 00:00:00